Reduction cardiovascular morbidity and mortality with the statins

Rex W. Force, PharmD

The hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors are recommended as major drugs in the treatment of hyperlipidemia by the second National Cholesterol Education Program (NCEP II) Expert Panel. These agents lower cholesterol by inhibiting the rate-limiting enzyme (HMG-CoA reductase) responsible for cholesterol synthesis in the liver. Secondarily, a compensatory mechanism of increasing low-density lipoprotein (LDL) receptors acts to decrease circulating LDL concentrations. Five HMG-CoA reductase inhibitors, or so-called "statins," are currently on the market: lovastatin (Mevacor), pravastatin (Pravachol), simvastatin (Zocor), fluvastatin (Lescol), and atorvastatin (Lipitor). These drugs differ in their pharmacokinetic profiles, potencies, and costs.

For several years controversy existed as to whether cholesterol lowering with pharmacotherapy was beneficial to patients. A great deal of biomedical literature is, it does not always support what clinicians do. We will avoid making conclusions that are not supported by POEMs. Nevertheless, POEMs should be incorporated into clinical practice. The rest is up to the reader. Blending POEMs with rational thought, clinical experience, and importantly, patient preferences can be the essence of the art of medicine.

We hope you will find these articles useful and easy to read. Your comments and suggestions are welcome. You may contact the editors through the editorial office of JABFP or on the Internet (http://clinic.isu.edu/drugsteps/intro.html). We hope the articles provide you with useful information that can be applied in everyday practice, and we look forward to your feedback.

Rex W. Force, PharmD, STEPPed Care Feature Editor
John Geyman, MD, Editor
Journal of the American Board of Family Practice

References
of information was available regarding the efficacy of the statins in lowering total cholesterol and LDL while raising high-density lipoprotein (HDL). This information, however, was disease-oriented evidence, meaning that data were not available regarding more important outcomes (decreased myocardial infarctions (MIs), strokes, and mortality). More recently, three trials\(^5\)\(^-\)\(^7\) with the statins have provided evidence that some agents might be useful for primary and secondary prevention of cardiovascular events and mortality. Importantly, these studies have provided the patient-oriented evidence that matters (POEMs) to patients and providers.

Methods
A MEDLINE search was performed for January 1983 through June 1997 using the search terms “anticholesteremic agents,” “HMG-CoA reductase inhibitors,” “cardiovascular diseases,” “myocardial infarction,” “mortality,” and “survival.” The search was limited to human clinical trials with the statins published in English language journals. Studies were selected if they had POEMs (cardiovascular disease, mortality, coronary artery bypass grafts [CABG], etc) as primary outcomes. The number needed to treat to prevent one negative outcome was then calculated and presented in tabular form. For completeness, other references reviewing the pharmacology and use of the statins were included at the discretion of the author. This review will examine the statins and their role in lowering plasma lipid levels to prevent cardiovascular disease by using the STEP approach: safety (an analysis of adverse effects that patients and providers care about), tolerability (pooled dropout rates from large clinical trials), effectiveness (how well the drugs work and in what patient population[s]), and price (cost of drug, but also cost effectiveness of therapy).

Safety and Tolerability
The safety of the statins has been well-established and has been recently reviewed elsewhere.\(^2\) More than 8000 patients received lovastatin for 48 weeks in the Expanded Clinical Evaluation of Lovastatin (EXCEL) trial.\(^6\)\(^,\)\(^9\) The most common adverse effect in EXCEL was constipation. Nevertheless, the incidence of constipation in the lovastatin-treated patients (6.0 percent) was only slightly higher than placebo (4.7 percent). Infrequent elevations of serum aminotransferases (alanine aminotransferase and aspartate aminotransferase) and creatine kinase did occur in the lovastatin group. These elevations were more common at doses of 40 to 80 mg/d. From these data about 2 to 6 percent of patients receiving more than 40 mg/d would have an elevation (two times normal) in aminotransferases and approximately 0.2 to 0.5 percent would have an elevation (10 times normal) in creatine kinase. Actual hepatitis or rhabdomyolysis are extremely uncommon; therefore, these increased laboratory values appear to have limited clinical significance. About 5.1 percent of the patients on placebo dropped out of the trial because of adverse events whereas 6.3 to 7.0 percent of patients receiving lovastatin regimens discontinued treatment because of adverse effects. Overall, about 85 percent of patients receiving placebo and lovastatin finished the 48-week trial.

Subsequent studies with simvastatin\(^5\) and pravastatin\(^6\)\(^,\)\(^7\) have shown that these agents are well-tolerated. In the Scandinavian Simvastatin Survival Study (4S),\(^5\) 6 percent of patients in both the placebo and simvastatin (40 mg/d) groups discontinued therapy because of adverse events during the 5-year trial. Specifically, serum aminotransferase elevations were not more common in the simvastatin group, and no cases of hepatitis were reported. Creatine kinase elevations occurred in 6 of 2221 (0.3 percent) and in 1 of 2223 (0.05 percent) of patients receiving simvastatin or placebo, respectively. A single patient developed rhabdomyolysis in the simvastatin group. Additionally, there were no differences between the groups with regard to cancers. Overall, 13 percent of patients stopped taking their tablets in the placebo group compared with 10 percent of patients receiving simvastatin.

In the West of Scotland Coronary Prevention Study (WOSCOPS)\(^6\) with pravastatin (40 mg/d), there were no significant differences in serum aminotransferase elevations, creatine kinase elevations, cancer development, or myalgias in the patients receiving pravastatin compared with those receiving placebo. Overall, 30.8 percent and 29.6 percent of patients withdrew from the 5-year study in the placebo and pravastatin groups, respectively. In a second pravastatin study, the Cholesterol and Recurrent Events (CARE) Trial,\(^7\) 86 percent and 94 percent of the patients in the
Table 1. Number Needed to Treat to Prevent a Single Adverse Outcome for Primary Prevention (WOSCOPS) and Secondary Prevention (CARE and 4S) Trials with the Statins Compared with Placebo.

<table>
<thead>
<tr>
<th>Events</th>
<th>WOSCOPS</th>
<th>Number Needed to Treat</th>
<th>CARE</th>
<th>4S</th>
</tr>
</thead>
<tbody>
<tr>
<td>Coronary artery bypass graft, angioplasty</td>
<td>125</td>
<td>21</td>
<td>17</td>
<td></td>
</tr>
<tr>
<td>Acute myocardial infarction</td>
<td>42*</td>
<td>33*</td>
<td>21</td>
<td></td>
</tr>
<tr>
<td>Stroke</td>
<td>NS</td>
<td>83</td>
<td>63</td>
<td></td>
</tr>
<tr>
<td>Death from coronary heart disease</td>
<td>NS</td>
<td>NS</td>
<td>29</td>
<td></td>
</tr>
<tr>
<td>Total mortality</td>
<td>111†</td>
<td></td>
<td>30</td>
<td></td>
</tr>
</tbody>
</table>

*Includes nonfatal myocardial infarction and death from coronary heart disease.
†P = 0.051.

WOSCOPS - West of Scotland Coronary Prevention Study, CARE - Cholesterol and Recurrent Events, 4S - Scandinavian Simvastatin Survival Study.
NS - not significantly different from placebo.

placebo and pravastatin groups, respectively, completed at least 4 years on the study protocol. There were no significant differences in the incidence of serum aminotransferase elevation, creatine kinase elevation, or myositis. The placebo group developed 161 cancers, whereas the pravastatin group developed 172 (P = NS). The pravastatin group, however, developed significantly more breast cancers (12 versus 1, P = 0.002). The authors speculate that this difference could be due to an unusually low incidence of breast cancer in the control group rather than an increased incidence in the pravastatin group.7

Information from smaller trials indicates that fluvastatin and atorvastatin share the risk of elevating serum transaminase and creatine kinase levels, as discussed above for the other statins.2,10 At high doses all of these drugs can induce tumors in rats and mice. At present, the clinical importance of this potential in humans is unknown.

Most pharmacokinetic drug interactions with the statins are relatively unimportant clinically. Rhabdomyolysis has occurred in patients receiving the statins in conjunction with gemfibrozil, niacin, cyclosporine, and erythromycin.2 The manufacturers of the statins state that patients should be monitored for hepatotoxicity, elevated creatine kinase levels, and muscle weakness.

Effectiveness

The statins markedly lower total and LDL cholesterol levels while causing mild elevations of HDL cholesterol levels. The potencies of the agents in lowering LDL cholesterol levels differ; maximal recommended doses of lovastatin (80 mg/d), pravastatin (40 mg/d), and simvastatin (40 mg/d) generally decrease LDL cholesterol levels by 25 to 40 percent. Fluvastatin is considered less potent and reduces LDL cholesterol levels by 20 to 25 percent at 40 mg/d.2 The new agent atorvastatin is the most potent statin available and lowers LDL cholesterol by 50 to 60 percent at a dose of 80 mg/d. Additionally, atorvastatin has the greatest effect on triglycerides when compared with the other statins.10 These findings, however, are disease-oriented evidence, and there are no data on the effects of fluvastatin and atorvastatin on cardiovascular morbidity and mortality. Limited data are available on the effect of lovastatin on these patient-oriented outcomes. The statins have not been compared head-to-head to evaluate patient-oriented outcomes; the only comparative studies available evaluate lipid-lowering effects.2 Until head-to-head morbidity and mortality trials of the statins are completed, clinicians should base their selection of a statin on the available POEMS.

The EXCEL trial was designed to evaluate the cholesterol-lowering efficacy of three different lovastatin regimens or placebo during a 48-week period in 8245 patients.8,9 Although the primary goals of the study were to evaluate the efficacy of the drug in lowering lipid levels and to determine the long-term safety of the agent, there were several cardiovascular events and deaths that warrant comment. Of the 36 deaths that occurred, 31 were from coronary heart disease, and 28 of these occurred in the lovastatin groups.3,8,9 It should be noted that EXCEL patients were those receiving treatment for primary and secondary prevention. A recent secondary prevention trial of lovastatin, 40 to 80 mg/d versus 2.5 mg/d, showed that the higher doses were effective in reducing the incidence of CABG.11 There was no placebo arm in the lipid-lowering portion of this trial, however.
Overall, neither mortality nor the occurrence of MIs or cancers was different between the groups. Eighty-five percent of patients complied with the treatment regimen during the 4-year study.

Since 1994 reports of three trials have been published describing POEMs with cholesterol lowering using pravastatin and simvastatin. The effects of these drugs on CABG and angioplasty, acute MI, stroke, death from coronary heart disease (CHD), and overall mortality in patients receiving primary and secondary prevention are summarized in Table 1.

WOSCOPS was designed as a primary prevention trial in high-risk patients. The trial was conducted in Scotland and consisted of 6545 men (mean age 55 years) who had mean baseline plasma cholesterol and LDL concentrations of 272 mg/dL and 192 mg/dL, respectively. The patients were randomly assigned to receive 40 mg of pravastatin or placebo each evening in a double-blind trial design. None of the patients had experienced an MI, and only 5 percent had angina. Forty-four percent were current smokers (an additional 34 percent were ex-smokers), they drank the equivalent of nearly 2 six-packs of beer per week, and 15 percent had hypertension. Their mean HDL level was 44 mg/dL. The primary end point of the study was the combined incidence of nonfatal MIs or death from CHD.

During the 5-year study, 7.9 percent of placebo and 5.5 percent of pravastatin patients experienced a definite primary outcome (P < 0.001). The number needed to treat to prevent a single adverse outcome has been calculated in Table 1. For example, to prevent the occurrence of a single definite MI or death from CHD, 42 patients would have to be treated for 5 years with pravastatin 40 mg/d. Overall mortality was reduced from 4.1 percent in the placebo group to 3.2 percent in the pravastatin group (P = 0.051) yielding a number needed to treat of 111.6

Two secondary prevention trials also showed the benefit of cholesterol-lowering therapy with statins. The CARE trial was a multicenter, double-blind trial investigating the effects of pravastatin on coronary events after MI. Pravastatin (40 mg/d) or placebo was administered to 3583 men and 576 women who had mean baseline total cholesterol and LDL concentrations of 209 mg/dL and 139 mg/dL, respectively. Their mean age was 59 years and mean HDL concentration was 39 mg/dL. Fifteen percent had diabetes, 43 percent had hypertension, and 21 percent were current smokers. The patients were a mean of 10 months post-MI. Like WOSCOPS, the primary end point of the study was the combined incidence of nonfatal MI or death from CHD. During the 5-year study period, 13.2 percent of placebo and 10.2 percent of pravastatin patients experienced a primary outcome (P = 0.003), yielding a number needed to treat of 33 for 5 years. Overall mortality was not significantly reduced in the pravastatin group. Interestingly, patients who had baseline LDL concentrations of less than 125 mg/dL did not experience any benefit from pravastatin therapy. This finding calls into question the use of statins to reduce cholesterol to less than 100 mg/dL in patients whose cholesterol concentrations are less than 125 mg/dL.7,12

The second trial demonstrating benefit of cholesterol-lowering therapy as secondary prevention, 4S, was a multicenter, double-blind trial of simvastatin (20 to 40 mg/d) in patients with previous MI or angina. At baseline, mean total cholesterol and LDL concentrations were 261 mg/dL and 188 mg/dL, respectively. One half of the patients were ex-smokers and about a quarter were current smokers, 26 percent were hypertensive, and 5 percent were diabetic. Two thirds of the patients were within 5 years of their first diagnosis of angina or MI. The mean age was 59 years and mean HDL concentration was 46 mg/dL. Eight-hundred twenty-seven women and 3617 men received active drug or placebo and were observed for years with the goal of reducing their total cholesterol concentrations to 116 to 201 mg/dL.

The primary end point of the study was overall mortality. During the study period, 11.5 percent of patients receiving placebo and 8.2 percent of patients receiving simvastatin died (P = 0.0003), yielding a number needed to treat of 30. Definite
Table 3. Drug STEPS Overview.

| Safety and Tolerability | Statins are well tolerated and safe. In large clinical trials, pooled drop-out rate is about 15%, not different from placebo. |
| Effectiveness | Simvastatin (in secondary prevention) and pravastatin (in primary and secondary prevention) have been shown to lower cardiovascular mortality and morbidity in well-defined patient populations. |
| Price | Statins typically cost $2 to $3 per day. Cost effectiveness models are positive. |
| Summary | With appropriate selection, cholesterol lowering with pravastatin and simvastatin can benefit some patients. |

acute MIs were significantly reduced in the simvastatin group (7.4 versus 12.1 percent with placebo). Based on these data, 21 patients would need to be treated with simvastatin for 5 years to prevent one MI. Other endpoints are provided in Table 1.

An assessment of the initial level of risk to the patient is essential for appropriate use of the statins.3,4,12 For example, in the CARE trial patients with LDL concentrations less than 125 mg/dL did not receive any benefit from pravastatin, while patients with LDL concentrations greater than 150 mg/dL had a 10 percent absolute reduction in risk of coronary events. In 4S, 59-year-old male patients with CHD and a total cholesterol of 261 mg/dL would be expected to live 15.6 years without treatment and 15.9 years with 5 years of treatment.13 Also of note, most trials of cholesterol lowering required 2 years of continuous medication before the treatment effect emerged. In patients with a life expectancy of less than 2 years, these agents are unlikely to provide a survival benefit.

Price

The cost of 1 month's supply of the statins is shown in Table 2. Typically these agents cost $40 to $110 per month depending on the dosing regimen.10 Numerous cost-effectiveness analyses have been published within the past 10 years; however, most of them were based on models of cholesterol lowering and the expected benefits on cardiovascular morbidity and mortality. Few data on the cost effectiveness of the statins are available since the above POEM data have been published. Recently Johannesson et al13 produced a sophisticated cost-effectiveness analysis based on the 4S trial. Depending on patient age and serum cholesterol concentration, simvastatin treatment resulted in varying cost savings per life-year gained for patients with CHD in this model. For example, in younger patients the costs of the intervention (simvastatin therapy and monitoring) were significantly less than the direct and indirect costs of the morbidity of coronary disease. In older patients the cost per life-year gained ranged from $1,200 to $13,300, with men having a lower cost per life-year gained than women. It should be noted that the costs of drugs and of various events (MI, CABG, etc) in Sweden were less than typical costs in the United States.

Summary

Based on the available literature, pravastatin and simvastatin have a role in lowering total cholesterol and LDL concentrations in patients with existing cardiovascular disease (Table 3). The result of lowering serum lipid levels with these agents is fewer MIs and CABGs. Pravastatin did not lower overall mortality as secondary prevention in patients with average serum cholesterol concentrations, whereas simvastatin did decrease mortality in higher risk patients. Additionally, in very high risk male patients, pravastatin has been shown to be effective for primary prevention of cardiovascular morbidity and mortality. Studies with lovastatin have not shown a benefit in decreasing the incidence of MI or death. Although one trial did show a decrease in CABGs with secondary preventive therapy with lovastatin, this trial was not placebo-controlled. Data are not available regarding the ability of fluvastatin or atorvastatin therapy to provide POEMs with cardiovascular disease. In general, the drugs are well-tolerated and cost from $2 to $3 a day.

With appropriate patient selection clinicians can expect simvastatin to provide benefits to patients with existing CHD and pravastatin to provide similar benefits in patients requiring primary or secondary prevention.

References

1. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel


